When ctDNA was detected in combined tumor-informed assays at baseline and after neoadjuvant therapy, most HRs for recurrence and mortality risk showed a trend toward higher values compared with non-tumor-informed assays. ctDNA test positivity predicted clinical recurrence an average of 4.53 months earlier (range: 0.98-11.6 months) than conventional radiological imaging techniques.
← all excerpts
Circulating tumor DNA predicts prognosis at different time points in patients with esophageal cancer: a systematic review and meta-analysis.
1
—
—